Yijia Hua

Suzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer.

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer.

Journal: eLife

Published: June 04, 2025

An open-label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2-negative metastatic breast cancer.

An open-label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2-negative metastatic breast cancer.

Journal: International journal of cancer

Published: February 18, 2025

m6A mRNA methylation initiated by METTL14 promotes STK11 translation and increases STK11 activity to induce anti-HER2 therapy resistance in breast cancer.

m6A mRNA methylation initiated by METTL14 promotes STK11 translation and increases STK11 activity to induce anti-HER2 therapy resistance in breast cancer.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: September 10, 2024

Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion.

Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: July 23, 2024

An Imbalance in Histone Modifiers Induces tRNA-Cys-GCA Overexpression and tRF-27 Accumulation by Attenuating Promoter H3K27me3 in Primary Trastuzumab-Resistant Breast Cancer.

An Imbalance in Histone Modifiers Induces tRNA-Cys-GCA Overexpression and tRF-27 Accumulation by Attenuating Promoter H3K27me3 in Primary Trastuzumab-Resistant Breast Cancer.

Journal: Cancers

Published: December 18, 2023

The war between the immune system and the tumor - using immune biomarkers as tracers.

The war between the immune system and the tumor - using immune biomarkers as tracers.

Journal: Biomarker research

Published: December 06, 2023

Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2-Positive Breast Cancer.

Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2-Positive Breast Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: December 04, 2023

Tyrosine kinase inhibitors in HER2-positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real-world study.

Tyrosine kinase inhibitors in HER2-positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real-world study.

Journal: MedComm

Published: August 24, 2023

tRF-27 competitively Binds to G3BPs and Activates MTORC1 to Enhance HER2 Positive Breast Cancer Trastuzumab Tolerance.

tRF-27 competitively Binds to G3BPs and Activates MTORC1 to Enhance HER2 Positive Breast Cancer Trastuzumab Tolerance.

Journal: International journal of biological sciences

Published: June 22, 2023

Exosome-Transmitted tRF-16-K8J7K1B Promotes Tamoxifen Resistance by Reducing Drug-Induced Cell Apoptosis in Breast Cancer.

Exosome-Transmitted tRF-16-K8J7K1B Promotes Tamoxifen Resistance by Reducing Drug-Induced Cell Apoptosis in Breast Cancer.

Journal: Cancers

Published: November 05, 2022

A positive feedback loop: RAD18-YAP-TGF-β between triple-negative breast cancer and macrophages regulates cancer stemness and progression.

A positive feedback loop: RAD18-YAP-TGF-β between triple-negative breast cancer and macrophages regulates cancer stemness and progression.

Journal: Cell death discovery

Published: February 04, 2022

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report.

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report.

Journal: Frontiers in oncology

Published: January 21, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026